Bortezomib remains a cornerstone treatment for multiple myeloma and mantle cell lymphoma, and Leeds's St James's University Hospital — one of Europe's largest cancer centres — manages substantial myeloma patient volumes requiring this proteasome inhibitor. Bortenat 3.5mg provides the same treatment at significantly reduced cost.
Bortenat is supplied as a lyophilised powder, administered subcutaneously or intravenously. The subcutaneous route is increasingly preferred in Leeds oncology practice, producing equivalent efficacy with lower peripheral neuropathy rates than IV administration. Standard myeloma dosing is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle, typically combined with dexamethasone and Lenalidomide or Cyclophosphamide.
Leeds hospital pharmacies can source Bortenat at competitive prices through licensed Indian suppliers with full WHO-GMP documentation for formulary approval processes.
Unnati Pharmax supplies Bortenat 3.5mg to Leeds and across the UK. Contact medshopy.com or WhatsApp +91 82650 41513.
Bortenat is supplied as a lyophilised powder, administered subcutaneously or intravenously. The subcutaneous route is increasingly preferred in Leeds oncology practice, producing equivalent efficacy with lower peripheral neuropathy rates than IV administration. Standard myeloma dosing is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle, typically combined with dexamethasone and Lenalidomide or Cyclophosphamide.
Leeds hospital pharmacies can source Bortenat at competitive prices through licensed Indian suppliers with full WHO-GMP documentation for formulary approval processes.
Unnati Pharmax supplies Bortenat 3.5mg to Leeds and across the UK. Contact medshopy.com or WhatsApp +91 82650 41513.
